Delta-Fly Pharma, Inc. (TYO:4598)
Japan · Delayed Price · Currency is JPY 99.00
-1.00 (-1.00%)
Oct 9, 2026, 3:30 PM JST
Delta-Fly Pharma Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
1.46B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | 300.00M | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.64B |
| Kohjin Bio | 4.69B |
| PhoenixBio | 1.42B |
| Human Metabolome Technologies | 1.42B |
| D. Western Therapeutics Institute | 247.00M |
| Veritas In Silico | 84.42M |
| Ribomic | 7.50M |
| FunPep Company | 1.00M |